These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 33647951

  • 1. Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after United States v. Caronia: An Analysis of Litigated Cases.
    Liu S, Mello MM, Kesselheim AS.
    J Health Polit Policy Law; 2021 Jun 01; 46(3):487-504. PubMed ID: 33647951
    [Abstract] [Full Text] [Related]

  • 2. United States v. Caronia: Off-Label Drug Promotion and First Amendment Balancing.
    Rabinowitz DP.
    Fordham Law Rev; 2018 Apr 01; 86(5):2595-623. PubMed ID: 29993225
    [Abstract] [Full Text] [Related]

  • 3. United States v. Caronia: The increasing strength of commercial free speech and potential new emphasis on classifying off-label promotion as "false and misleading".
    Scheineson MJ, Cuevas G.
    Food Drug Law J; 2013 Apr 01; 68(2):201-16, iii. PubMed ID: 24640469
    [Abstract] [Full Text] [Related]

  • 4. Truth, Falsity, and Fraud: Off-Label Drug Settlements and the Future of the Civil False Claims Act.
    Krause JH.
    Food Drug Law J; 2016 Apr 01; 71(3):401-40. PubMed ID: 29140064
    [Abstract] [Full Text] [Related]

  • 5. Snake oil salesmen or purveyors of knowledge: off-label promotions and the commercial speech doctrine.
    Bagley CE, Mitts J, Tinsley RJ.
    Cornell J Law Public Policy; 2013 Apr 01; 23(2):337-93. PubMed ID: 25330567
    [Abstract] [Full Text] [Related]

  • 6. Commercial speech and off-label drug uses: what role for wide acceptance, general recognition and research incentives?
    Gilhooley M.
    Am J Law Med; 2011 Apr 01; 37(2-3):258-77. PubMed ID: 21847881
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
    Vilhelmsson A, Davis C, Mulinari S.
    PLoS Med; 2016 Jan 01; 13(1):e1001945. PubMed ID: 26812151
    [Abstract] [Full Text] [Related]

  • 11. False Claims Act prosecution did not deter off-label drug use in the case of neurontin.
    Kesselheim AS, Darby D, Studdert DM, Glynn R, Levin R, Avorn J.
    Health Aff (Millwood); 2011 Dec 01; 30(12):2318-27. PubMed ID: 22147859
    [Abstract] [Full Text] [Related]

  • 12. The ban on "off-label" pharmaceutical promotion: constitutionally permissible prophylaxis against false or misleading commercial speech?
    Greenwood K.
    Am J Law Med; 2011 Dec 01; 37(2-3):278-98. PubMed ID: 21847882
    [Abstract] [Full Text] [Related]

  • 13. Court rules that FDA cannot restrict off-label marketing.
    Roehr B.
    BMJ; 2015 Aug 11; 351():h4367. PubMed ID: 26265632
    [No Abstract] [Full Text] [Related]

  • 14. Off-label use of medical products in radiation therapy: summary of the report of AAPM Task Group No. 121.
    Thomadsen BR, Heaton HT, Jani SK, Masten JP, Napolitano ME, Ouhib Z, Reft CS, Rivard MJ, Robin TT, Subramanian M, Suleiman OH.
    Med Phys; 2010 May 11; 37(5):2300-11. PubMed ID: 20527564
    [Abstract] [Full Text] [Related]

  • 15. Free speech rights outweigh restrictions on promoting drugs off label, court rules.
    Roehr B.
    BMJ; 2012 Dec 06; 345():e8324. PubMed ID: 23220261
    [No Abstract] [Full Text] [Related]

  • 16. The next forum for unraveling FDA off-label marketing rules: State and federal legislatures.
    Sinha MS, Kesselheim AS.
    PLoS Med; 2018 May 06; 15(5):e1002564. PubMed ID: 29738523
    [Abstract] [Full Text] [Related]

  • 17. Origins of the prohibition against off-label promotion.
    Coleman TS.
    Food Drug Law J; 2014 May 06; 69(2):161-236, i. PubMed ID: 25163210
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine.
    Wang B, Studdert DM, Sarpatwari A, Franklin JM, Landon J, Kesselheim AS.
    PLoS One; 2017 May 06; 12(4):e0175313. PubMed ID: 28388667
    [Abstract] [Full Text] [Related]

  • 20. Off-label, not off-limits: the FDA needs to create a safe harbor for off-label drug use.
    Howard P, Copland J.
    Mo Med; 2013 May 06; 110(2):106-9. PubMed ID: 23724473
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.